Sign in
BLPH Stock Price, Chart, Stats & News
Bellerophon Therapeutics, Inc.
Save
BLPH chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 10.86% |
ROA | -249.92% |
ROE | -164.21% |
D/E | 0.08x |
Interest coverage ratio | -165.81x |
BLPH valuation
P/E | – |
P/S | – |
P/B | 0.05x |
P/CF | -0.01x |
P/FCF | -0.01x |
P/OCF | -0.01x |
PEG | -0.00x |
EV multiple | -0.31x |
About
Bellerophon Therapeutics, Inc. is a U. S.-based clinical-stage pharmaceutical company primarily focused on developing novel therapies for various cardiopulmonary conditions. Its flagship product is INOpulse, a proprietary platform designed to deliver pulsatile nitric oxide, specifically targeting pulmonary hypertension (PH).
Similar securities
Based on sector and market capitalization
Report issue